MX2008008278A - Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg. - Google Patents
Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg.Info
- Publication number
- MX2008008278A MX2008008278A MX2008008278A MX2008008278A MX2008008278A MX 2008008278 A MX2008008278 A MX 2008008278A MX 2008008278 A MX2008008278 A MX 2008008278A MX 2008008278 A MX2008008278 A MX 2008008278A MX 2008008278 A MX2008008278 A MX 2008008278A
- Authority
- MX
- Mexico
- Prior art keywords
- dinucleotide
- toll
- modifications
- novel synthetic
- receptors containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere al uso terapéutico de oligonucleótidos como agentes moduladores inmunes en aplicaciones de inmunoterapia; más en particular, la invención provee composiciones de oligonucleótidos moduladores inmunes para usar en métodos para generar una respuesta inmune o para tratar un paciente que necesita modulación inmune; los oligonucleótidos moduladores inmunes de la invención de preferencia comprenden pirimidinas y purinas novedosas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75233505P | 2005-12-20 | 2005-12-20 | |
US82145806P | 2006-08-04 | 2006-08-04 | |
PCT/US2006/048362 WO2007084237A2 (en) | 2005-12-20 | 2006-12-19 | Novel synthetic agonists of toll-like receptors containing cg dinucleotide modifications |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008008278A true MX2008008278A (es) | 2008-10-01 |
Family
ID=38288084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008008278A MX2008008278A (es) | 2005-12-20 | 2006-12-19 | Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20080279785A1 (es) |
EP (1) | EP1962896A4 (es) |
JP (1) | JP2009520502A (es) |
AU (1) | AU2006336242A1 (es) |
CA (1) | CA2632943A1 (es) |
MX (1) | MX2008008278A (es) |
WO (1) | WO2007084237A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
EP2423335B1 (en) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
CN101820908A (zh) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
CA2750499A1 (en) * | 2009-01-30 | 2010-08-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
CA3033133C (en) | 2009-03-25 | 2021-11-09 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
JP2017537619A (ja) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | 球状核酸ナノ粒子複合体の配列特異的細胞内取込 |
JP6121597B1 (ja) * | 2016-06-09 | 2017-04-26 | 株式会社スリービー | 免疫応答活性化サイトカイン産生促進剤およびTh17細胞分化促進剤 |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
US11806364B2 (en) | 2017-09-28 | 2023-11-07 | Industry-Academic Cooperation Foundation, Yonsei University | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
TW244371B (es) * | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO2002026757A2 (en) * | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
KR101137572B1 (ko) * | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역조절 올리고뉴클레오티드 |
US7276486B2 (en) * | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
-
2006
- 2006-12-19 AU AU2006336242A patent/AU2006336242A1/en not_active Abandoned
- 2006-12-19 WO PCT/US2006/048362 patent/WO2007084237A2/en active Application Filing
- 2006-12-19 EP EP06849308A patent/EP1962896A4/en not_active Withdrawn
- 2006-12-19 JP JP2008547425A patent/JP2009520502A/ja active Pending
- 2006-12-19 CA CA002632943A patent/CA2632943A1/en not_active Abandoned
- 2006-12-19 MX MX2008008278A patent/MX2008008278A/es active IP Right Grant
- 2006-12-19 US US11/641,590 patent/US20080279785A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1962896A2 (en) | 2008-09-03 |
EP1962896A4 (en) | 2009-08-05 |
CA2632943A1 (en) | 2007-07-26 |
US20080279785A1 (en) | 2008-11-13 |
WO2007084237A2 (en) | 2007-07-26 |
JP2009520502A (ja) | 2009-05-28 |
WO2007084237A3 (en) | 2008-05-02 |
AU2006336242A1 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008008278A (es) | Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg. | |
TW200637522A (en) | Skin treatment articles and methods | |
MX2009008918A (es) | Activacion de celulas que presentan antigeno humano a traves de clec-6. | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
MXPA06011327A (es) | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. | |
PL1830881T3 (pl) | Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
UA83311C2 (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
TN2010000060A1 (en) | Proteasome inhibitors | |
MY145447A (en) | Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile | |
TN2010000044A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
EP1784639A4 (en) | PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD | |
ECSP11011534A (es) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak | |
MX2009003122A (es) | Inhibidores de tirosina cinasa de bruton. | |
TW200608966A (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
HK1147949A1 (en) | Hair care compositions and methods of treating hair | |
MX2009009591A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
TW200637836A (en) | Cytotoxic agents comprising new taxanes | |
RS20080246A (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
MX2009009117A (es) | Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2. | |
UA87494C2 (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
TW200640893A (en) | Cytotoxic agents comprising new C-2 modified taxanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |